New Delhi, July 23 -- Cipla, which posted its financial results for the June quarter on Thursday, saw its profits dip 39% over softer US sales. However, the company expects sequential sales momentum in the US, driven by new launches in the coming quarter, chief executive Achin Gupta said.

"Our pipeline for the year is very promising. It includes several significant launches, particularly comprising three respiratory assets and one key peptide opportunity, which we keenly look forward to in terms of approvals and launches," Gupta told reporters in a post-results press conference.

Cipla's net profit for the quarter fell 39% year-on-year to Rs.789 crore, due to an absence of two key products, lenalidomide and lanreotide, compared to the pr...